Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials
Latest Information Update: 09 Feb 2022
Price :
$35 *
At a glance
- Drugs Perampanel (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 01 Feb 2022 Results assessing efficacy and safety of perampanel in patients with sporadic amyotrophic lateral sclerosis published in the Journal of Neurology
- 14 Jan 2021 Status changed from active, no longer recruiting to completed.
- 01 May 2020 Results assessing safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis, presented at the 72nd Annual Meeting of the American Academy of Neurology.